Cigna Group 8-K Report, Corporate Update (Jan 31, 2024)

On January 31, 2024, The Cigna Group (CI) disclosed a definitive agreement to sell its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC) for a total transaction value of approximately $3.7 billion^a.

Cigna expects to record an estimated pre-tax loss of $1.5 billion^b in net income as of December 31, 2023, primarily reflecting asset write-offs and costs to sell. Importantly, this non-cash-type charge is excluded from adjusted income from operations, so the fourth-quarter 2023 adjusted results are not affected. The transaction is expected to close in the first quarter of 2025, subject to regulatory approvals and customary closing conditions, and carries no financing condition.

Management states the deal is expected to be accretive to adjusted EPS in 2025, and that the majority of proceeds will go toward share repurchases, consistent with its capital deployment priorities. Cigna also reaffirmed its 2024 outlook of at least $28^c per share in adjusted income from operations and its long-term adjusted EPS growth target of 10% to 13%, with updated guidance to come on the February 2, 2024 fourth-quarter earnings release. Strategically, management frames the divestiture as a move to concentrate capital on Evernorth Health Services and Cigna Healthcare, while Evernorth will continue providing pharmacy benefit services to the sold Medicare businesses under a four-year services agreement.

For investors, the key takeaways are the large reported GAAP loss, the clean separation of that loss from adjusted metrics, the buyback-oriented use of proceeds, and the execution risk tied to regulatory approval and a closing timeline more than a year away. The filing's forward-looking statements flag risks including regulatory approval, deal timing, separation difficulties, and Medicare-related government program uncertainty.